Ipca Labs Q4 Review - Upbeat Guidance, Execution Remains Key: ICICI Direct

CRAMS and small volume APIs and Intermediates manufacturing facility in North Carolina. (Source: Company Website).

Ipca Labs Q4 Review - Upbeat Guidance, Execution Remains Key: ICICI Direct


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Ipca Laboratories Ltd.'s Q4 revenues remained subdued growing just 3.8% YoY to Rs 1115 crore.

Strong YoY growth of 19.7% in export formulations to Rs 338 crore was partly offset by active pharmaceutical ingredient sales decline of 5.5% YoY to Rs 260 crore.

Domestic formulations remained flat at Rs 434 crore versus Rs 431 crore in Q4 FY20.

Ebitda margins improved 484 basis points YoY to 20.5% due to better gross margins and lower other expenditure.

Ebitda grew 35.8% YoY to Rs 229 crore.

Profit after tax grew 87.5% YoY to Rs 161 crore (our estimate: Rs 204 crore).

Click on the attachment to read the full report:

ICICI Direct Ipca Labs Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.